Bionomics Ltd ADR (BNOX)

$0.25 +0.01 (4.20%)
Market Cap 4.47M
Revenue (ttm) 0.00
Net Income (ttm) -15.49M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 7,434,400
Avg Vol 12,314,951
Day's Range N/A - N/A
Shares Out 17.65M
Stochastic %K 20%
Beta 0.26
Analysts Strong Sell
Price Target $6.00

Latest News on BNOX

Bionomics Announces Supreme Court of New South Wales Approves Bionomics' Re-Domiciliation

Dec 16, 2024, 4:05 PM EST - 4 weeks ago

Bionomics Announces Supreme Court of New South Wales Approves Bionomics' Re-Domiciliation

Results of Scheme Meeting

Dec 12, 2024, 4:05 PM EST - 5 weeks ago

Results of Scheme Meeting

Bionomics to Present at the 2024 American College of Neuropsychopharmacology Annual Meeting

Dec 3, 2024, 4:05 PM EST - 6 weeks ago

Bionomics to Present at the 2024 American College of Neuropsychopharmacology Annual Meeting

Bionomics Reminds Shareholders to Cast their Vote for Re-Domiciliation from Australia to the United States

Dec 2, 2024, 5:01 PM EST - 6 weeks ago

Bionomics Reminds Shareholders to Cast their Vote for Re-Domiciliation from Australia to the United States

Bionomics Provides an Update on Re-domiciliation via Scheme of Arrangement

Nov 8, 2024, 4:15 PM EST - 2 months ago

Bionomics Provides an Update on Re-domiciliation via Scheme of Arrangement

Bionomics Receives Milestone Payment of AUS$1M from Carina Biotech for BNC101 Partnered Legacy Oncology Program

Nov 4, 2024, 4:15 PM EST - 2 months ago

Bionomics Receives Milestone Payment of AUS$1M from Carina Biotech for BNC101 Partnered Legacy Oncology Program

Bionomics to Present at the ThinkEquity Conference

Oct 23, 2024, 6:00 AM EDT - 3 months ago

Bionomics to Present at the ThinkEquity Conference

Bionomics to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

Oct 14, 2024, 8:00 AM EDT - 3 months ago

Bionomics to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

Bionomics Limited announces intention to re-domicile to the United States

Oct 1, 2024, 6:30 AM EDT - 3 months ago

Bionomics Limited announces intention to re-domicile to the United States

Bionomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 6:30 AM EDT - 4 months ago

Bionomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA on the Development of BNC210 in Post-Traumatic Stress Disorder

Jul 31, 2024, 6:30 AM EDT - 6 months ago

Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA on the Development of BNC210 in Post-Traumatic Stress Disorder

Bionomics to Provide a Corporate Update and Discuss End-of-Phase 2 Meeting Outcomes on the Development of BNC210 in PTSD on July 31, 2024

Jul 29, 2024, 4:30 PM EDT - 6 months ago

Bionomics to Provide a Corporate Update and Discuss End-of-Phase 2 Meeting Outcomes on the Development of BNC210 in PTSD on July 31, 2024

Bionomics Initiates AFFIRM-1, a Phase 3 Clinical Trial with BNC210 for Social Anxiety Disorder

Jul 18, 2024, 6:30 AM EDT - 6 months ago

Bionomics Initiates AFFIRM-1, a Phase 3 Clinical Trial with BNC210 for Social Anxiety Disorder

Bionomics Limited Announces Private Placement of up to $70.0 Million

May 31, 2024, 8:00 AM EDT - 8 months ago

Bionomics Limited Announces Private Placement of up to $70.0 Million

Bionomics to Present at the 2024 American Society of Clinical Psychopharmacology Annual Meeting

May 20, 2024, 6:30 AM EDT - 8 months ago

Bionomics to Present at the 2024 American Society of Clinical Psychopharmacology Annual Meeting

Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder

Mar 21, 2024, 6:00 AM EDT - 10 months ago

Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder

Bionomics to Present at the 2024 BIO CEO & Investor Conference

Feb 22, 2024, 4:30 PM EST - 11 months ago

Bionomics to Present at the 2024 BIO CEO & Investor Conference

Bionomics Provides a Review of 2023 and of 2024 Plans

Jan 22, 2024, 6:00 AM EST - 1 year ago

Bionomics Provides a Review of 2023 and of 2024 Plans

Bionomics to Present at Biotech Showcase™ 2024

Jan 5, 2024, 6:00 AM EST - 1 year ago

Bionomics to Present at Biotech Showcase™ 2024

Bionomics Presents Detailed Data on the Validity and Reliability of the Subjective Units of Distress Scale at the 2023 American College of Neuropsychopharmacology Annual Meeting

Dec 6, 2023, 8:00 AM EST - 1 year ago

Bionomics Presents Detailed Data on the Validity and Reliability of the Subjective Units of Distress Scale at the 2023 American College of Neuropsychopharmacology Annual Meeting

Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA and Solidifies Plans to Initiate the Registrational Program for BNC210 in Social Anxiety Disorder

Oct 16, 2023, 8:00 AM EDT - 1 year ago

Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA and Solidifies Plans to Initiate the Registrational Program for BNC210 in Social Anxiety Disorder

Bionomics announces positive results in trial of treatment for PTSD

Sep 28, 2023, 6:13 AM EDT - 1 year ago

Bionomics announces positive results in trial of treatment for PTSD

Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)

Sep 28, 2023, 6:00 AM EDT - 1 year ago

Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)

Bionomics Announces Update on the α7 Nicotinic Acetylcholine Receptor (nAChR) Positive Allosteric Modulator (PAM) Collaboration with MSD

Sep 14, 2023, 6:00 AM EDT - 1 year ago

Bionomics Announces Update on the α7 Nicotinic Acetylcholine Receptor (nAChR) Positive Allosteric Modulator (PAM) Collaboration with MSD

Bionomics Completes Last Patient Last Visit in the Phase 2b ATTUNE Study for Post-Traumatic Stress Disorder (PTSD) and Confirms Expected 2023 Milestones with its Lead Asset BNC210

Aug 23, 2023, 6:00 AM EDT - 1 year ago

Bionomics Completes Last Patient Last Visit in the Phase 2b ATTUNE Study for Post-Traumatic Stress Disorder (PTSD) and Confirms Expected 2023 Milestones with its Lead Asset BNC210

Quarterly Activities and Cashflow Report

Jul 31, 2023, 6:00 AM EDT - 1 year ago

Quarterly Activities and Cashflow Report

Bionomics Announces Intention to Delist from the Australian Securities Exchange (ASX)

Jul 25, 2023, 6:00 AM EDT - 1 year ago

Bionomics Announces Intention to Delist from the Australian Securities Exchange (ASX)

Bionomics Announces Key Leadership Updates to Drive U.S.-Focused Transformation and Next Stage of Strategic Growth

Jul 3, 2023, 6:00 AM EDT - 1 year ago

Bionomics Announces Key Leadership Updates to Drive U.S.-Focused Transformation and Next Stage of Strategic Growth

Bionomics to Present at Upcoming June Investor Conferences

Jun 15, 2023, 8:00 AM EDT - 1 year ago

Bionomics to Present at Upcoming June Investor Conferences

Bionomics Announces Upcoming Poster Presentation at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

May 30, 2023, 6:00 AM EDT - 1 year ago

Bionomics Announces Upcoming Poster Presentation at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

Bionomics Announces the Completion of Enrollment in Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)

Apr 27, 2023, 6:00 AM EDT - 1 year ago

Bionomics Announces the Completion of Enrollment in Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)

Bionomics Reports Promising Full Results Analysis from PREVAIL Phase 2 Study of BNC210 Social Anxiety Disorder (SAD)

Mar 8, 2023, 7:00 PM EST - 2 years ago

Bionomics Reports Promising Full Results Analysis from PREVAIL Phase 2 Study of BNC210 Social Anxiety Disorder (SAD)

Bionomics' Half-Year Report

Feb 23, 2023, 6:00 AM EST - 2 years ago

Bionomics' Half-Year Report

Bionomics Reports Topline Results in PREVAIL Phase 2 Study of BNC210 in Social Anxiety Disorder

Dec 18, 2022, 7:34 PM EST - 2 years ago

Bionomics Reports Topline Results in PREVAIL Phase 2 Study of BNC210 in Social Anxiety Disorder

Bionomics appoints Spyridon “Spyros” Papapetropoulos as President and Chief Executive Officer

Dec 15, 2022, 6:35 PM EST - 2 years ago

Bionomics appoints Spyridon “Spyros” Papapetropoulos as President and Chief Executive Officer

Bionomics Announces Accepted Abstract and Upcoming Poster Presentations at the American College of Neuropsychopharmacology (ACNP) 2022 Annual Meeting

Dec 2, 2022, 6:00 AM EST - 2 years ago

Bionomics Announces Accepted Abstract and Upcoming Poster Presentations at the American College of Neuropsychopharmacology (ACNP) 2022 Annual Meeting

Bionomics Limited Announces Closing of US$5 Million Underwritten Offering of American Depositary Shares in the United States

Nov 21, 2022, 6:13 PM EST - 2 years ago

Bionomics Limited Announces Closing of US$5 Million Underwritten Offering of American Depositary Shares in the United States

Bionomics Limited Announces Pricing of Underwritten Offering of American Depositary Shares in the United States

Nov 16, 2022, 6:36 PM EST - 2 years ago

Bionomics Limited Announces Pricing of Underwritten Offering of American Depositary Shares in the United States

Bionomics Limited to Participate in Upcoming November Investor Conferences

Nov 2, 2022, 6:00 AM EDT - 2 years ago

Bionomics Limited to Participate in Upcoming November Investor Conferences

Quarterly Activities Report for September 2022

Oct 25, 2022, 6:00 AM EDT - 2 years ago

Quarterly Activities Report for September 2022

Bionomics Receives R&D Tax Incentive Refund for FY2022 of A$4.6 million

Oct 18, 2022, 6:00 AM EDT - 2 years ago

Bionomics Receives R&D Tax Incentive Refund for FY2022 of A$4.6 million

Bionomics Limited to Participate in the Cantor Neurology & Psychiatry Conference

Oct 4, 2022, 6:00 AM EDT - 2 years ago

Bionomics Limited to Participate in the Cantor Neurology & Psychiatry Conference

Bionomics to Host KOL Webinar on BNC210 and Social Anxiety Disorder

Sep 21, 2022, 6:00 AM EDT - 2 years ago

Bionomics to Host KOL Webinar on BNC210 and Social Anxiety Disorder

Bionomics to Participate in Upcoming September Investor Conferences

Aug 31, 2022, 6:00 AM EDT - 2 years ago

Bionomics to Participate in Upcoming September Investor Conferences

Bionomics reports Full Year Financial Results

Aug 25, 2022, 6:00 AM EDT - 2 years ago

Bionomics reports Full Year Financial Results

Bionomics Receives R&D Tax Incentive Refund for FY2021 of A$2.1M

Aug 8, 2022, 6:00 AM EDT - 2 years ago

Bionomics Receives R&D Tax Incentive Refund for FY2021 of A$2.1M

Quarterly Activities Report for June 2022

Jul 29, 2022, 6:00 AM EDT - 2 years ago

Quarterly Activities Report for June 2022

Bionomics to Participate in William Blair's Biotech Focus Conference 2022

Jul 8, 2022, 6:00 AM EDT - 2 years ago

Bionomics to Participate in William Blair's Biotech Focus Conference 2022

Bionomics Limited to Participate in the H.C. Wainwright Mental Health Conference

Jun 27, 2022, 6:00 AM EDT - 2 years ago

Bionomics Limited to Participate in the H.C. Wainwright Mental Health Conference

Bionomics Investor Webinar

Jun 13, 2022, 4:30 PM EDT - 2 years ago

Bionomics Investor Webinar